AlphAIalphai — Financial news for AI agents
fool.comAUG 203 min read$CELC

Celcuity (CELC) Q2 2026 Earnings Call Transcript

Celcuity (CELC) reported Q2 2026 net loss of $78.9M ($1.44/ share), up from $45.3M last year. Cash reserves total $754M, with $557.2M raised from a convertible note offering. The company launched Revtopik, a drug for advanced breast cancer, and plans a supplemental New Drug Application. Clinical trials showed significant reduction in disease progression risk. Management expects cash to fund operations into 2029.

Original reporting
fool.com
Published Aug 20, 2026, 11:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 12:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Celcuity (CELC) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$CELCNeutralMed
01

Why it matters

The earnings release provides fresh data on cash position, loss magnitude, and capital structure, influencing short-term price action and longer-term valuation.

02

Market read

The announcement combines earnings disappointment with a significant capital raise and regulatory approval, creating a mixed short-term trading signal for the stock.

03

What to watch

Potential revenue from Revtopik pricing and upcoming VIKTORIA-2 trial data could materially improve outlook.

Relevance 7/10Novelty 8/10Timing: Q2 2026 earnings release

Background

Celcuity reported its Q2 2026 financial results, highlighted a net loss, a $575M convertible note offering, and FDA approval of its lead product Revtopik.

Company-level read

Ticker impact

$CELCNeutralMedium confidence
Context

Q2 2026 earnings call disclosed a $78.9M net loss, $575M convertible note raise and FDA approval of Revtopik.

Expected impact

Potential near-term downside on earnings miss, followed by stabilization as cash runway and approval are priced in.

Evidence & confidence

Losses and higher SG&A weigh on valuation, but $754M cash and FDA approval are material positive catalysts.

Market effects

Sector

Biotech sector may see renewed interest in PI3K/mTOR inhibitors after FDA approval.

Regional

U.S. biotech investors may adjust exposure to small-cap pipelines.

Global

Limited to companies developing similar targeted therapies.

Counterpoint

What could challenge this read

Despite the loss, the cash runway and FDA approval could support a bounce if the market overreacts to the earnings miss.

Key entities

  • Company
    Celcuity

    Biopharma developing gedatolisib and Revtopik.

  • Executive
    Brian F. Sullivan

    CEO and cofounder of Celcuity.

Read at source← All news

Related articles

AUG 24
$CELCLow

How Investors May Respond To Celcuity (CELC) Deepening Losses As Gedatolisib Commercial Plans Advance

Celcuity Inc. (CELC) reported a net loss of $78.86 million in Q2 2026, with first-half losses widening to $131.71 million. The company is advancing gedatolisib and preparing for commercialization, with FDA approval of REVTORPYK in July. Investors focus on whether REVTORPYK revenue can offset increased cash burn. Celcuity projects $817.9 million revenue and $267.5 million earnings by 2029, implying a 77% upside from current prices.

simplywall.st3 min
AUG 16
$CELCMed

The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status

Celcuity (CELC) reported a wider Q2 net loss of $78.86 million and higher basic loss per share in August 2026. The company said Revtopik received FDA approval and a preferred Category 1 NCCN guideline recommendation for HR-positive, HER2-negative advanced breast cancer, which it says could affect its commercialization outlook. The article cites 2029 revenue of $817.9 million and earnings of $267.5 million.

simplywall.st6 min
AUG 15
$CELCMed

Celcuity Q2 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.

yahoo.com5 min
AUG 13
$CELCMedAI 8/10

Celcuity Inc. (CELC): Results of Operations and Financial Condition

Celcuity Inc. (CELC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 celc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update • REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or meta

SEC EDGAR 8-K7 min
AUG 1
$CELCMed

Newly FDA-approved Revtorpyk wins NCCN listing

Celcuity (NASDAQ: CELC) said its Revtorpyk (gedatolisib) plus fulvestrant, with or without palbociclib, was added to NCCN Guidelines as a preferred Category 1 option for HR+, HER2- advanced or metastatic breast cancer after endocrine therapy progression. FDA approved Revtorpyk on July 14, 2026 for HR+/HER2- disease without detected PIK3CA mutation.

thepharmaletter.com4 min